Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
Go back to Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer| JAZZ PHARMACEUTICAL (NASDAQ: JAZZ) | Delayed: 240.07 -6.74 (2.73%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $246.81 | 52 Week High | $160.00 | |||
| Open | $240.00 | 52 Week Low | $95.80 | |||
| Day High | $244.71 | P/E | 44.62 | |||
| Day Low | $239.11 | EPS | $5.38 | |||
| Volume | 467,907 | |||||
